ArticleObesity surgery2026
Safety Profile of Primary Intragastric Balloon Placement in Class III Obesity: An MBSAQIP Analysis of 4,555 Patients.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntragastric balloon (IGB) therapy is a minimally invasive endoscopic intervention primarily utilized for weight reduction in patients with Class I and II obesity. While less frequently utilized in individuals with Class III obesity (BMI ≥ 40 kg/m²), IGB placement may be considered as a bridge to bariatric surgery or when surgery is contraindicated or declined. However, data regarding short-term safety outcomes in this higher-risk population remain limited.
objectiveThis study aims to compare 30-day safety outcomes after IGB placement in patients with BMI ≥ 40 kg/m² versus BMI < 40 kg/m².
methodsThis was a retrospective cohort study of 4,555 patients undergoing primary IGB placement from 2016 to 2023 using the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) database. Primary outcomes included hospital length of stay and 30-day rates of outpatient intravenous (IV) treatments, emergency department (ED) visits, readmissions, reoperations, interventions, and mortality. Patients were stratified by BMI ≥ 40 kg/m² and BMI < 40 kg/m² for comparative analysis using propensity score-matching (PSM). 962 pairs were identified for PSM.
resultsPatients with BMI ≥ 40 kg/m² were younger on average and more likely to be male and non-Hispanic Black. This group exhibited a higher prevalence of associated medical problems, including diabetes, obstructive sleep apnea, hypertension, renal insufficiency, immunosuppressant use, thromboembolic events, and therapeutic anticoagulation use. After adjustment for baseline differences, patients with BMI ≥ 40 kg/m² were more likely to require a postoperative hospital length of stay longer than one day (p = 0.003). No significant differences in 30-day outpatient IV treatments, ED visits, readmissions, reoperations, interventions, or mortality, were observed.
conclusionPatients with BMI ≥ 40 kg/m² exhibited a greater burden of associated medical problems and longer hospital length of stay, but otherwise demonstrated comparable short-term safety outcomes to those with BMI < 40 kg/m². These findings suggest comparable 30-day hospital-based safety outcomes after IGB placement in patients with BMI ≥ 40 kg/m² compared with BMI < 40 kg/m².
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.